The article by Sarfaraz K. Niazi, PhD, critiques the irrationality surrounding biosimilars, suggesting that regulatory ...

Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and ...

Ivo Abraham, PhD, RN, University of Arizona Cancer Center, analyzes the need for innovative risk-sharing models to promote biosimilar development and utilization.

Number 5: The FDA has approved Pavblu (aflibercept-ayyh), the fifth biosimilar referencing Eylea (aflibercept).1 The new ...

The combination of trastuzumab biosimilar and pertuzumab with chemotherapy was effective in treating HER2-positive breast cancer, offering high safety and affordability. HER2-positive breast cancer ...

Survey of Clinicians: Lower Cost of Biosimilars Is the Main Driver of Treatment Choice in IBD ...